Antivirulence activity of azithromycin in Pseudomonas aeruginosa

Frontiers in Microbiology

Volumn 5, Issue APR, 2014, Pages

  Imperi, Francesco ^a   Leoni, Livia ^b   Visca, Paolo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Antibiotic; Cystic fibrosis; Inflammation; Macrolide; Regulation; Virulence

Indexed keywords

AZITHROMYCIN; EXOTOXIN; MACROLIDE; PHOSPHOLIPASE C; PYOCYANINE; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; LUNG FUNCTION; LUNG INFECTION; LYMPHOCYTE ACTIVATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; SEPSIS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84899670756     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00178     Document Type: Article

References (73)

1. Aminov, R. I. (2013). Biotic acts of antibiotics. Front. Microbiol. 4:241. doi: 10.3389/fmicb.2013.00241
2. Amsden, G. W. (2005). Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 55, 10-21. doi: 10.1093/jac/dkh519
3. Anderson, R., Steel, H. C., Cockeran, R., von Gottberg, A., de Gouveia, L., Klugman, K. P., et al. (2007). Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J. Antimicrob. Chemother. 60, 1155-1158. doi: 10.1093/jac/dkm338
4. Baumann, U., King, M., App, E. M., Tai, S., König, A., Fischer, J. J., et al. (2004). Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J. 11, 151-155.
5. Blumer, J. L. (2005). Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int. J. Antimicrob. Agents 3, S143-S147. doi: 10.1016/S0924-8579(05)80320-6
6. Buyck, J. M., Plésiat, P., Traore, H., Vanderbist, F., Tulkens, P. M., and Van Bambeke, F. (2012). Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin. Infect. Dis. 55, 534-542. doi: 10.1093/cid/cis473
7. Cegelski, L., Marshall, G. R., Eldridge, G. R., and Hultgren, S. J. (2008). The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 6, 17-27. doi: 10.1038/nrmicro2244
8. Clatworthy, A. E., Pierson, E., and Hung, D. T. (2007). Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3, 541-548. doi: 10.1038/nchembio.2007.24
9. Clement, A., Tamalet, A., Leroux, E., Ravilly, S., Fauroux, B., and Jais, J. P. (2006). Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61, 895-902. doi: 10.1136/thx.2005.057950
10. Coggan, K. A., and Wolfgang, M. C. (2012). Global regulatory pathways and cross-talk control Pseudomonas aeruginosa environmental lifestyle and virulence phenotype. Curr. Issues Mol. Biol. 14, 47-70.
11. Driscoll, J. A., Brody, S. L., and Kollef, M. H. (2007). The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67, 351-368. doi: 10.2165/00003495-200767030-00003
12. Equi, A., Balfour-Lynn, I. M., Bush, A., and Rosenthal, M. (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360, 978-984. doi: 10.1016/S0140-6736(02)11081-6
13. Favre-Bonté, S., Köhler, T., and Van Delden, C. (2003). Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J. Antimicrob. Chemother. 52, 598-604. doi: 10.1093/jac/dkg397
14. Fernebro, J. (2011). Fighting bacterial infections-future treatment options. Drug Resist. Updat. 14, 125-139. doi: 10.1016/j.drup.2011.02.001
15. Ferrer, I. R., Araki, K., and Ford, M. L. (2011). Paradoxical aspects of rapamycin immunobiology transplantation. Am. J. Transplant. 11, 654-659. doi: 10.1111/j.1600-6143.2011.03473
16. Fleet, J. E., Guha, K., Piper, S., Banya, W., Bilton, D., and Hodson, M. E. (2013). A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic. J. Cyst. Fibros. 12, 49-53. doi: 10.1016/j.jcf.2012.05.010
17. Foulds, G., Shepard, R. M., and Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A):73-82. doi: 10.1093/jac/25.suppl_A.73
18. Frangipani, E., Visaggio, D., Heeb, S., Kaever, V., Cámara, M., Visca, P., et al. (2014). The Gac/Rsm and cyclic-di-GMP signalling networks coordinately regulate iron uptake in Pseudomonas aeruginosa. Environ. Microbiol. 16, 676-688. doi: 10.1111/1462-2920.12164
19. Giamarellos-Bourboulis, E. J. (2008). Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int. J. Antimicrob. Agents 32(Suppl.1):S39-S43. doi: 10.1016/j.ijantimicag.2008.06.004
20. Gillis, R. J., and Iglewski, B. H. (2004). Azithromycin retards Pseudomonas aeruginosa biofilm formation. J. Clin. Microbiol. 42, 5842-5845. doi: 10.1128/JCM.42.12.5842-5845.2004
21. Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A., et al. (1987). Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 31, 1948-1954. doi: 10.1128/AAC.31.12.1948
22. Gödeke, J., Pustelny, C., and Häussler, S. (2013). Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57, 1617-1624. doi: 10.1128/AAC.02582-12
23. Hicks, L. A., Taylor, T. H., and Hunkler, R. J. (2013). U.S. outpatient antibiotic prescribing, 2010. N. Engl. J. Med. 368, 1461-1462. doi: 10.1056/NEJMc1212055
24. Hodge, S., Hodge, G., Jersmann, H., Matthews, G., Ahern, J., Holmes, M., et al. (2008). Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178, 139-148. doi: 10.1164/rccm.200711-1666OC
25. Hoffmann, N., Lee, B., Hentzer, M., Rasmussen, T. B., Song, Z., Johansen, H. K., et al. (2007). Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-). mice. Antimicrob. Agents Chemother. 51, 3677-3687. doi: 10.1128/AAC.01011-06
26. Ichimiya, T., Takeoka, K., Hiramatsu, K., Hirai, K., Yamasaki, T., and Nasu, M. (1996). The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 42, 186-191. doi: 10.1159/000239440
27. Imamura, Y., Higashiyama, Y., Tomono, K., Izumikawa, K., Yanagihara, K., Ohno, H., et al. (2005). Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 49, 1377-1380. doi: 10.1128/AAC.49.4.1377-1380.2005
28. Imperi, F., Massai, F., Facchini, M., Frangipani, E., Visaggio, D., Leoni, L., et al. (2013). Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc. Natl. Acad. Sci. U.S.A. 110, 7458-7463. doi: 10.1073/pnas.1222706110
29. Itkin, I. H., and Menzel, M. L. (1970). The use of macrolide antibiotic substances in the treatment of asthma. J. Allergy 45, 146-162. doi: 10.1016/0021-8707(70)90124-3
30. Jaffé, A., Francis, J., Rosenthal, M., and Bush, A. (1998). Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351, 420. doi: 10.1016/S0140-6736(05)78360-4
31. Kai, T., Tateda, K., Kimura, S., Ishii, Y., Ito, H., Yoshida, H., et al. (2009). A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa. Pulm. Pharmacol. Ther. 22, 483-486. doi: 10.1016/j.pupt.2009.04.004
32. Kanoh, S., and Rubin, B. K. (2010). Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23, 590-615. doi: 10.1128/CMR.00078-09
33. Kita, E., Sawaki, M., Oku, D., Hamuro, A., Mikasa, K., Konishi, M., et al. (1991). Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J. Antimicrob. Chemother. 27, 273-284. doi: 10.1093/jac/27.3.273
34. Kohler, T., Dumas, J. L., and Van Delden, C. (2007). Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary phase killing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51, 4243-4248. doi: 10.1128/AAC.00613-07
35. Law, G. L., Tisoncik-Go, J., Korth, M. J., and Katze, M. G. (2013). Drug repurposing: a better approach for infectious disease drug discovery? Curr. Opin. Immunol. 25, 588-592. doi: 10.1016/j.coi.2013.08.004
36. Legssyer, R., Huaux, F., Lebacq, J., Delos, M., Marbaix, E., Lebecque, P., et al. (2006). Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir. Res. 7, 134. doi: 10.1186/1465-9921-7-134
37. Lutz, L., Pereira, D. C., Paiva, R. M., Zavascki, A. P., and Barth, A. L. (2012). Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol. 12:196. doi: 10.1186/1471-2180-12-196
38. McAlister, V. C., Mahalati, K., Peltekian, K. M., Fraser, A., and MacDonald, A. S. (2002). A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther. Drug Monit. 24, 346-350. doi: 10.1097/00007691-200206000-00004
39. Miyairi, S., Tateda, K., Fuse, E. T., Ueda, C., Saito, H., Takabatake, T., et al. (2006). Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J. Med. Microbiol. 55, 1381-1387. doi: 10.1099/jmm.0.46658-0
40. Molinari, G., Guzman, C. A., Pesce, A., and Schito, G. C. (1993). Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 31, 681-688. doi: 10.1093/jac/31.5.681
41. Molinari, G., Paglia, P., and Schito, G. C. (1992). Inhibition of motility of Pseudomonas aeruginosa and proteus mirabilis by subinhibitory concentrations of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 11, 469-471. doi: 10.1007/BF01961867
42. Morita, Y., Kimura, N., Mima, T., Mizushima, T., and Tsuchiya, T. (2001). Roles of MexXY-and MexAB multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1. J. Gen. Appl. Microbiol. 47, 27-32. doi: 10.2323/jgam.47.27
43. Nagino, K., and Kobayashi, H. (1997). Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin. Microbiol. Infect. 3, 432-439. doi: 10.1111/j.1469-0691.1997.tb00279.x
44. Nalca, Y., Jänsch, L., Bredenbruch, F., Geffers, R., Buer, J., and Häussler, S. (2006). Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50, 1680-1688. doi: 10.1128/AAC.50.5.1680-1688.2006
45. Nguyen, D., Emond, M. J., Mayer-Hamblett, N., Saiman, L., Marshall, B. C., and Burns, J. L. (2007). Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr. Pulmonol. 42, 533-541. doi: 10.1002/ppul.20620
46. Nicolau, D. P., Banevicius, M. A., Marangos, M. N., Klepser, M. E., Quintiliani, R., and Nightingale, C. H. (1997). Influence of adjunct azithromycin on the mortality of experimental Pseudomonas aeruginosa sepsis. Int. J. Antimicrob. Agents 8, 239-241. doi: 10.1016/S0924-8579(97)00017-4
47. Nicolau, D. P., Banevicius, M. A., Nightingale, C. H., and Quintiliani, R. (1999). Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob. Agents Chemother. 43, 3033-3035.
48. Pal, S. (2006). A journey across the sequential development of macrolides and ketolides related to erythromycin. Tetrahedron 62, 3171-3200. doi: 10.1016/j.tet.2005.11.064
49. Pérez-Martínez, I., and Haas, D. (2011). Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55, 3399-3405. doi: 10.1128/AAC.01801-10
50. Poehlsgaard, J., and Douthwaite, S. (2005). The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 3, 870-881. doi: 10.1038/nrmicro1265
51. Rasko, D. A., and Sperandio, V. (2010). Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9, 117-128. doi: 10.1038/nrd3013
52. Ratjen, F., Saiman, L., Mayer-Hamblett, N., Lands, L. C., Kloster, M., Thompson, V., et al. (2012). Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 142, 1259-1266. doi: 10.1378/chest.12-0628
53. Retsema, J., and Fu, W. (2001). Macrolides: structures and microbial targets. Int. J. Antimicrob. Agents 18(Suppl. 1):S3-S10. doi: 10.1016/S0924-8579(01)00401-0
54. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob. Agents Chemother. 31, 1939-1947. doi: 10.1128/AAC.31.12.1939
55. Saiman, L., Anstead, M., Mayer-Hamblett, N., Lands, L. C., Kloster, M., Hocevar-Trnka, J., et al. (2010). Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303, 1707-1715. doi: 10.1001/jama.2010.563
56. Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., et al. (2003). Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290, 1749-1756. doi: 10.1001/jama.290.13.1749
57. Salmond, R. J., and Zamoyska, R. (2011). The influence of mTOR on T helper cell differentiation and dendritic cell function. Eur. J. Immunol. 41, 2137-2141. doi: 10.1002/eji.201141523
58. Schultz, M. J. (2004). Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. 54, 21-28. doi: 10.1093/jac/dkh309
59. Skindersoe, M. E., Alhede, M., Phipps, R., Yang, L., Jensen, P. O., Rasmussen, T. B., et al. (2008). Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 3648-3663. doi: 10.1128/AAC.01230-07
60. Southern, K. W., Barker, P. M., Solis-Moya, A., and Patel, L. (2012). Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 2004, CD002203. doi: 10.1002/14651858.CD002203.pub4
61. Spreer, A., Kerstan, H., Böttcher, T., Gerber, J., Siemer, A., Zysk, G., et al. (2003). Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob. Agents Chemother. 47, 2649-2654. doi: 10.1128/AAC.47.8.2649-2654.2003
62. Steel, H. C., Theron, A. J., Cockeran, R., Anderson, R., and Feldman, C. (2012). Pathogen-and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012, 5842-5862. doi: 10.1155/2012/584262
63. Sugimura, M., Maseda, H., Hanaki, H., and Nakae, T. (2008). Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 4141-4144. doi: 10.1128/AAC.00511-08
64. Tateda, K., Comte, R., Pechere, J. C., Kohler, T., Yamaguchi, K., and Van Delden, C. (2001). Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 1930-1933. doi: 10.1128/AAC.45.6.1930-1933.2001
65. Tateda, K., Hirakata, Y., Furuya, N., Ohno, A., and Yamaguchi, K. (1993). Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37, 675-680. doi: 10.1128/AAC.37.4.675
66. Tateda, K., Ishii, Y., Hirakata, Y., Matsumoto, T., Ohno, A., and Yamaguchi, K. (1994). Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity. J. Antimicrob. Chemother. 34, 931-942. doi: 10.1093/jac/34.6.931
67. Tateda, K., Ishii, Y., Matsumoto, T., Furuya, N., Nagashima, M., Matsunaga, T., et al. (1996). Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother. 40, 2271-2275.
68. Tsai, W. C., Hershenson, M. B., Zhou, Y., and Sajjan, U. (2009). Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm. Res. 58, 491-501. doi: 10.1007/s00011-009-0015-9
69. van Delden, C., Köhler, T., Brunner-Ferber, F., François, B., Carlet, J., and Pechère, J. C. (2012). Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 38, 1118-1125. doi: 10.1007/s00134-012-2559-3
70. Wargo, M. J., Gross, M. J., Rajamani, S., Allard, J. L., Lundblad, L. K., Allen, G. B., et al. (2011). Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 184, 345-354. doi: 10.1164/rccm.201103-0374OC
71. Washington, J. A., and Wilson, W. R. (1985). Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin. Proc. 60, 271-278. doi: 10.1016/S0025-6196(12)60219-5
72. Wei, Q., and Ma, L. Z. (2013). Biofilm matrix and its regulation in Pseudomonas aeruginosa. Int. J. Mol. Sci. 14, 20983-21005. doi: 10.3390/ijms141020983
73. Wilms, E. B., Touw, D. J., and Heijerman, H. G. (2006). Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther. Drug Monit. 28, 219-225. doi: 10.1097/01.ftd.0000195617.69721.a5